# Monte Rosa Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/monte-rosa-therapeutics

- Industry: Biotechnology
- Headquarters: Boston, US
- Website: www.monterosatx.com
- Total disclosed funding: $181M
- Latest round: Series C (Mar 11, 2021)
- Investors on record: 16

## About

Founded in 2018 and Based in Massachusetts, US, Monte Rosa Therapeutics, Inc. operates as a biotechnology company that uses a protein degradation platform for developing cancer therapeutics. The firm has raised total funding of USD 223.5 million as of March 2021 and In June 2021, Monte Rosa Therapeutics, Inc. raised USD 222.3 million in an IPO, selling 11.7 million shares at USD 19 per share on the Nasdaq under the ticker symbol "GLUE". As of 2021, the company's CEO is Markus Warmuth.

Monte Rosa Therapeutics, Inc. develops molecular glues to treat cancer and other autoimmune diseases. The company also provides a protein degradation platform, called QuEEN to rationally design small molecules which reprogram ubiquitin ligases to eliminate disease drivers previously deemed undruggable.

The company plans to advance its lead development candidate into the clinic, accelerate pipeline growth and bolster its platform capabilities to rationally design and develop small molecule degraders.

## Funding rounds

- Series C, Mar 11, 2021, $95M — New Enterprise Associates, T Rowe Price, Versant Ventures, HBM Partners, Aisling Capital, Fidelity Investments, GV, BlackRock, Casdin Capital, RTW Investments, Cormorant Asset Management, Sixty Degree Capital, Amzak Capital Management, Avoro Capital Advisors, CI Global Asset Management
- Series B, Feb 22, 2021, $5M — HBM Partners
- Series B, Sep 15, 2020, $48M — New Enterprise Associates, Versant Ventures, HBM Partners, Aisling Capital, GV, CI Investments, Casdin Capital, Cormorant Asset Management, Sixty Degree Capital, Amzak Capital Management
- Series A, May 26, 2020, $33M — New Enterprise Associates, Versant Ventures

## Investors

- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series A, Series B, Series C
- Versant Ventures (https://capitalatlas.ai/funds/versant-ventures) — Series A, Series B, Series C
- HBM Partners (https://capitalatlas.ai/funds/hbm-partners) — Series B, Series C
- Aisling Capital (https://capitalatlas.ai/funds/aisling-capital) — Series B, Series C
- GV (https://capitalatlas.ai/funds/gv) — Series B, Series C
- CI Investments — Series B
- Casdin Capital (https://capitalatlas.ai/funds/casdin-capital) — Series B, Series C
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series B, Series C
- Sixty Degree Capital (https://capitalatlas.ai/funds/sixty-degree-capital) — Series B, Series C
- Amzak Capital Management (https://capitalatlas.ai/funds/amzak-capital-management) — Series B, Series C
- T Rowe Price (https://capitalatlas.ai/funds/t-rowe-price) — Series C
- Fidelity Investments (https://capitalatlas.ai/funds/fidelity-investments) — Series C
- BlackRock (https://capitalatlas.ai/funds/blackrock) — Series C
- RTW Investments (https://capitalatlas.ai/funds/rtw-investments) — Series C
- Avoro Capital Advisors — Series C
- CI Global Asset Management (https://capitalatlas.ai/funds/ci-global-asset-management) — Series C